NIKI (Niki BioSolutions) Research & Development: $0.33 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NIKI Niki BioSolutions Inc NIKI
34 GF Score
Price $6.23
! 1 Warning Sign
View Full Analysis

What is Niki BioSolutions Research & Development?

Niki BioSolutions NIKI -4.76% 34 Research & Development is $0.33 Mil as of Dec. 2025. GuruFocus rates NIKI with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Niki BioSolutions's Research & Development for the three months ended in Dec. 2025 was $0.09 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.33 Mil.

Niki BioSolutions  (NAS:NIKI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Niki BioSolutions Research & Development Related Terms

Niki BioSolutions Research & Development Historical Data

* Premium members only.

The historical data trend for Niki BioSolutions's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Niki BioSolutions Research & Development Chart

Niki BioSolutions Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 10.87 9.22 5.20 2.20 0.35

Niki BioSolutions Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 0.00 0.24 0.09 0.00
NIKI
34GF Score
Niki BioSolutions Inc NIKI
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Niki BioSolutions Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.33 Mil mean?
Niki BioSolutions (NIKI) has a Research & Development of $0.33 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Niki BioSolutions and its competitors.
Is Niki BioSolutions' Research & Development too high?
Niki BioSolutions' current Research & Development is $0.33 Mil. Overall, Niki BioSolutions has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Niki BioSolutions' Research & Development compare to KAPA and LIMN?
Niki BioSolutions' Research & Development of $0.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Niki BioSolutions and its competitors. Niki BioSolutions's current Research & Development is $0.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niki BioSolutions stock overvalued right now?
Niki BioSolutions (NIKI) has a current Research & Development of $0.33 Mil. The current Research & Development is $0.33 Mil. Niki BioSolutions' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Niki BioSolutions (NIKI), the current Research & Development is $0.33 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Niki BioSolutions Business Description

Address 17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
34GF Score

Get the complete analysis for NIKI

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.23
Price